Favipiravir vs. Deferiprone: Tautomeric, photophysical, in vitro biological studies, and binding interactions with SARS-Cov-2-MPro/ACE2

Favipiravir vs. Deferiprone: Tautomeric, photophysical, in vitro biological studies, and binding interactions with SARS-Cov-2-MPro/ACE2

Coronavirus disease 2019 (COVID-19) still remains the most disastrous infection continuously affecting millions of people worldwide. Herein, we performed a comparative study between the anti-influenza drug favipiravir (FAV) and the anti-thalassemia drug deferiprone (DFP) in order to examine their po...

Full description

Bibliographic Details
Main Authors: Nikolay T. Tzvetkov, Martina I. Peeva, Maya G. Georgieva, Vera Deneva, Aneliya A. Balacheva, Ivan P. Bogdanov, Maria Ponticelli, Luigi Milella, Kiril Kirilov, Maima Matin, Hans-Georg Stammler, Atanas G. Atanasov, Liudmil Antonov
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Current Research in Biotechnology
Subjects:
Favipiravir
Deferiprone
Tautomer-based drug design
COVID-19
Molecular modelling
Tautomerism
Online Access:http://www.sciencedirect.com/science/article/pii/S2590262824000029

Internet

http://www.sciencedirect.com/science/article/pii/S2590262824000029

Similar Items